Fig. 1: SOLTI-1805 TOT-HER3 clinical trial and associated translational study framework. | Nature Communications

Fig. 1: SOLTI-1805 TOT-HER3 clinical trial and associated translational study framework.

From: Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response

Fig. 1

a SOLTI-1805 TOT-HER3 trial design and translational study design. b Representative examples of H&E staining of a patient’s tumor with high CelTIL response and a patient’s tumor with low CelTIL response. H&E stainings were conducted for all baseline (n = 114) and day 21 samples (n = 114). c CelTIL score change in 114 samples of the SOLTI-1805 TOT-HER3 trial part A and part B combined in all patients, in patients with clinical response at day 21 (n = 40), and in patients without clinical response at day 21 (C1D21) (n = 56). Red lines represent increases at day 21 while blue lines represent decreases at day 21. P-values (p) were determined by two-tailed unpaired t tests. Source data are provided as a Source Data file.

Back to article page